Wegovy pill searches are rising in the UK, but it is important to understand what is — and is not — currently available. Wegovy (semaglutide 2.4 mg) is licensed in the UK exclusively as a subcutaneous injection, not as a pill. While an oral form of semaglutide exists under the brand name Rybelsus, it is approved only for type 2 diabetes management at lower doses. This article explains the current licensing position, NHS eligibility criteria, how to use Wegovy safely, its side effect profile, and which licensed oral alternatives are available in the UK for weight management.

Does Wegovy Come as a Pill in the UK?

Wegovy is not available as a pill in the UK — it is licensed exclusively as a subcutaneous injection. No oral version of Wegovy has received MHRA or EMA approval for weight management.

Wegovy is not currently available as a pill in the UK. It is licensed and supplied exclusively as a subcutaneous injection — meaning it is administered under the skin, typically in the abdomen, thigh, or upper arm. Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of a naturally occurring gut hormone, and is supplied as single-use pre-filled pens with dose escalation to a typical maintenance dose of 2.4 mg once weekly. Because semaglutide is a peptide-based molecule, it is broken down by digestive enzymes when taken orally in standard formulations, which is why the injectable route has historically been preferred at this dose.

It is worth noting that an oral form of semaglutide does exist — branded as Rybelsus — but this is licensed at lower doses (3 mg, 7 mg, and 14 mg) specifically for the management of type 2 diabetes, not for weight management. Rybelsus uses a special absorption enhancer (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, or SNAC) to allow limited absorption through the stomach lining. It is not interchangeable with Wegovy and is not approved by the Medicines and Healthcare products Regulatory Agency (MHRA) for obesity treatment.

There is ongoing research into higher-dose oral semaglutide formulations for weight management — for example, the investigational OASIS-1 trial examined oral semaglutide 50 mg — and early clinical data have shown promise. However, these formulations remain investigational and, at the time of publication, no oral version of Wegovy has received MHRA or European Medicines Agency (EMA) approval for use in the UK for weight management. Patients should be cautious of any product marketed as a "Wegovy pill," as no such licensed product currently exists, and unregulated alternatives may pose significant safety risks. Regulatory status should be verified with the MHRA or EMA at the time of reading.

Who Is Eligible for Wegovy on the NHS?

NICE guidance (TA875) recommends Wegovy for adults with a BMI of 35 kg/m² or above, at least one weight-related comorbidity, and engagement with a specialist NHS weight management service.

Access to Wegovy (semaglutide 2.4 mg) on the NHS is governed by NICE guidance (TA875), published in March 2023. This guidance recommends Wegovy as an option for weight management in adults who meet all of the following criteria:

• BMI of 35 kg/m² or above (or lower thresholds — typically reduced by approximately 2.5 kg/m² — for people from certain minority ethnic backgrounds, including Black, Asian, and other minority ethnic groups, where equivalent metabolic risk occurs at a lower BMI)

• At least one weight-related comorbidity, such as type 2 diabetes, hypertension, obstructive sleep apnoea, or cardiovascular disease

• Engagement with a specialist weight management service (typically NHS tier 3 or tier 4) that provides multidisciplinary support, including dietary, physical activity, and behavioural interventions

NICE also specifies that Wegovy should be used for a maximum of two years within the NHS pathway, reflecting the current evidence base and resource considerations.

The UK SmPC advises that treatment should be reviewed if a patient has not achieved at least 5% of their initial body weight after six months on the maintenance dose (or the maximum tolerated dose). Discontinuation should also be considered if the patient is unable to tolerate a dose of at least 1.7 mg. Wegovy is not recommended during pregnancy; women who are planning a pregnancy should stop treatment at least two months before attempting to conceive.

Regarding thyroid and endocrine history: the UK SmPC advises caution in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2), based on non-clinical C-cell tumour findings in rodents; the relevance of these findings to humans is currently unknown.

NHS availability remains subject to phased rollout and supply constraints. The NHS England implementation plan has prioritised specialist tier 3 and tier 4 weight management services. Patients interested in accessing Wegovy should speak with their GP, who can refer them to an appropriate service if they meet the eligibility criteria. Private prescriptions are also available through regulated clinics; patients should ensure any prescriber is registered with the General Medical Council (GMC) and that the medication is dispensed by a GPhC-registered pharmacy.

How to Use Wegovy Safely and What to Expect

Wegovy is injected once weekly using a pre-filled pen, with doses escalated over 16–20 weeks to a 2.4 mg maintenance dose to minimise gastrointestinal side effects.

Wegovy is administered once weekly via a single-use pre-filled pen, on the same day each week. The dose is gradually increased over 16 to 20 weeks to minimise gastrointestinal side effects — a process known as dose escalation:

• Weeks 1–4: 0.25 mg once weekly

• Weeks 5–8: 0.5 mg once weekly

• Weeks 9–12: 1.0 mg once weekly

• Weeks 13–16: 1.7 mg once weekly

• Week 17 onwards: 2.4 mg once weekly (maintenance dose)

The injection can be given at any time of day, with or without food. Patients should rotate injection sites to reduce the risk of localised skin reactions.

Missed doses: If a dose is missed and the next scheduled dose is more than 48 hours away, the missed dose can be administered; otherwise, it should be skipped and the next dose taken on the usual day. If two or more consecutive doses are missed, patients should contact their prescriber, as a temporary return to a lower dose may be recommended to reduce the risk of gastrointestinal side effects on restarting.

In clinical trials (the STEP programme, including STEP 1 published in the New England Journal of Medicine), participants using Wegovy alongside lifestyle intervention achieved an average weight loss of approximately 15% of body weight over 68 weeks, compared to around 2.4% with placebo. Weight loss typically begins within the first four weeks, with the most significant reductions occurring during the dose escalation phase and continuing through the maintenance period.

Wegovy works best as part of a comprehensive programme that includes reduced-calorie dietary changes and increased physical activity. It is not a standalone solution. Regular follow-up with a healthcare professional is important to monitor progress, manage side effects, and assess ongoing suitability.

Family planning: Wegovy must not be used during pregnancy. Women of childbearing potential should use effective contraception during treatment and should stop Wegovy at least two months before planned conception, as the medicine may remain in the body for some time after the last dose. Patients should discuss family planning with their GP or prescriber.

Common Side Effects and MHRA Safety Guidance

The most common side effects are gastrointestinal, including nausea affecting up to 44% of users; serious risks include pancreatitis, gallbladder problems, and dehydration-related kidney injury.

Like all medicines, Wegovy can cause side effects, though not everyone will experience them. The most commonly reported adverse effects are gastrointestinal in nature and are generally more pronounced during the dose escalation phase. These include:

• Nausea (affecting up to 44% of users in clinical trials)

• Vomiting

• Diarrhoea or constipation

• Abdominal discomfort or bloating

• Burping or acid reflux

These effects typically improve as the body adjusts to the medication. Eating smaller meals, avoiding high-fat or spicy foods, and staying well hydrated can help manage symptoms. Injection site reactions — such as redness, bruising, or mild swelling — are also relatively common but usually resolve quickly.

Important safety information, in line with the UK SmPC and MHRA guidance:

• Pancreatitis: Wegovy has been associated with a small increased risk of pancreatitis. Patients should seek urgent medical attention if they develop severe, persistent abdominal pain that may radiate to the back.

• Gallbladder problems: There have been reports of gallstones and gallbladder inflammation, particularly in the context of rapid weight loss. Report any new upper abdominal pain or jaundice to a healthcare professional promptly.

• Dehydration and kidney injury: Severe vomiting or diarrhoea can lead to dehydration. Patients should maintain adequate fluid intake and seek medical advice if they experience reduced urine output, dizziness, or other signs of dehydration, as acute kidney injury has been reported.

• Diabetic retinopathy: Rapid improvement in blood glucose control — particularly in people with type 2 diabetes, especially those on insulin — may temporarily worsen diabetic retinopathy. Patients with a history of this condition should be monitored closely.

• Hypoglycaemia: When Wegovy is used alongside insulin or a sulfonylurea in people with type 2 diabetes, there is an increased risk of low blood sugar (hypoglycaemia). Dose adjustments of the concomitant diabetes medication may be required; patients should discuss this with their prescriber.

• Heart rate: A small increase in resting heart rate has been observed; this should be monitored during treatment.

• Thyroid C-cell tumours: Based on animal studies, there is a theoretical risk of thyroid C-cell tumours; this has not been confirmed in humans, but patients should report any lump in the neck, difficulty swallowing, or persistent hoarseness to their GP.

When to seek help:

• Call 999 immediately for signs of a severe allergic reaction (anaphylaxis), such as difficulty breathing, severe swelling of the face or throat, or collapse.

• Contact your GP or call 111 for persistent vomiting, signs of dehydration, a lump in the neck, or other concerning symptoms that are not an emergency.

Any suspected adverse reactions to Wegovy should be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk. Reports can be submitted by patients, carers, or healthcare professionals.

Oral Alternatives to Wegovy Available in the UK

Orlistat and Mysimba are the main licensed oral weight management medicines in the UK, though neither matches the clinical efficacy demonstrated by Wegovy in trials.

For patients who are unable or unwilling to use injectable treatments, there are several licensed oral options for weight management and related metabolic conditions available in the UK. It is important to note that none currently match the weight loss efficacy demonstrated by Wegovy in clinical trials.

Orlistat (branded as Xenical, or available as a generic; also available over the counter as Alli at a lower dose) is the most established oral weight loss medication licensed in the UK. It works by inhibiting pancreatic lipase, an enzyme responsible for breaking down dietary fat, thereby reducing fat absorption by approximately 30%. NICE guidance recommends orlistat for adults with a BMI of ≥30 kg/m² (or ≥28 kg/m² with weight-related risk factors). Treatment should generally be continued beyond three months only if the patient has lost at least 5% of their initial body weight. Common side effects include oily stools, flatulence, and faecal urgency, particularly if dietary fat intake is not reduced.

Mysimba (naltrexone/bupropion) is a licensed oral combination medicine for weight management in adults with a BMI of ≥30 kg/m², or ≥27 kg/m² with weight-related comorbidities, used alongside a reduced-calorie diet and increased physical activity. It acts on areas of the brain involved in appetite regulation and reward. Key contraindications include uncontrolled hypertension, a history of seizures, and current or recent use of opioid medicines. Common side effects include nausea, headache, and insomnia. It is important to note that NICE (TA494) did not recommend Mysimba for routine NHS commissioning on cost-effectiveness grounds, although it remains a licensed medicine in the UK and may be available via private prescription or in specific clinical circumstances.

Rybelsus (oral semaglutide), as noted above, is licensed for type 2 diabetes management rather than obesity, and does produce modest weight loss as a secondary benefit. It is not a direct substitute for Wegovy and should not be used off-label for weight management without specialist guidance.

Several newer agents are under investigation, including oral tirzepatide and higher-dose oral semaglutide formulations. These remain investigational and have not received MHRA or EMA approval for weight management in the UK at the time of publication.

Patients should always consult a GP or pharmacist before starting any weight management medication, including over-the-counter products, to ensure suitability and safety. Self-prescribing or purchasing unlicensed products online carries significant health risks and should be avoided.

Frequently Asked Questions